Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer's disease: risks or benefits.

Abstract

Behavioral problems produce excess disability that can be potentially devastating in cognitively impaired patients. These behavioral symptoms can be a major cause of stress, anxiety and concern for caregivers. While psychotropic drugs are frequently used to control these symptoms, they have the potential for significant side effects, which include sedation, disinhibition, depression, falls, incontinence, parkinsonism and akathisias. On examination of the consequences of adverse events, somnolence, as well as postural instability and postural hypotension, have been noted. All patients with Alzheimer's disease (AD) and other progressive dementias will advance through stages of moderate-to-severe AD unless effective treatments suspend transition from mild deterioration to dementia, or competitive mortality truncates survival. Treatment trials suggest that these patients respond to both disease-modifying (such as inhibitors of cholinesterase and butirrylcholinesterase) and symptomatic (such as neuroleptics) agents. Relatively few studies have been conducted in this patient population, and more information regarding the type of behavioral disturbances exhibited, how best to measure them in this disabled population and their optimum treatment are urgently needed.

• Authors: Rita Moretti, Paola Torre, Rodolfo M Antonello, Gilberto Pizzolato
• Journal: Expert review of neurotherapeutics (Expert Rev Neurother) Vol. 6 Issue 5 Pg. 705-10 (May 2006) ISSN: 1744-8360 [Electronic] England
• PMID: 16734518 (Publication Type: Journal Article, Review)

Chemical References

• Antipsychotic Agents

Topics

• Alzheimer Disease (psychology)
• Antipsychotic Agents (therapeutic use)
• Anxiety (drug therapy, etiology)
• Humans
• Psychomotor Agitation (drug therapy, etiology)